Behaviour of hypertensive crisis

Authors

  • Leonardo Reyes Corona HOSPITAL MUNICIPAL “GELACIO CALAÑA” NIQUERO
  • Manuel René Reytor Gutiérrez HOSPITAL MUNICIPAL “GELACIO CALAÑA” NIQUERO
  • Armando Corona Castellanos HOSPITAL MUNICIPAL “GELACIO CALAÑA” NIQUERO

Keywords:

HYPERTENSION /drug therapy, ANTIHYPERTENSIVE AGENTS /therapeutic use, HIPERTENSIÓN/epidemiology, CLINICAL EVOLUTION

Abstract

It was performed a descriptive prospective and longitudinal study in “Gelacio Calaña” hospital from Niquero during the period January- December 2006. The universe of study was formed by all patients that came to the guard-room of our hospital manifesting hypertensive crisis (200patients) from them, 128 patients of different sexes, ages and races were selected. This study had as a main objective to determine the behaviour of hypertensive crisis in the studied period. Some variables were studied such as, age, sex, and race, frequent causes, symptoms at the time of hospitalizing and crisis evolution, feminine sex prevailed, age group of 61 to 70 years and black race. The symptoms at the time of hospitalizing were the precordial pain (the most influenced causes) when hypertensive crisis appeared were the idiopathies. The hypertensive encephalopathy were the most frequent crisis. Evolution was satisfactory because the majority of crisis were jugulated.  

Downloads

Download data is not yet available.

References

1. Nawarskas JJ, Crawford MH. Avances recientes en el tratamiento de las crisis hipertensivas. Cardiol Clin Annu Drugs Ther. 2004; 2: 21-33.

2. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure: The fifth Report. Arch Intern Med. 1999; 153: 154-83.

3. J.N. C.IV. Abdelwahab W, Frishman W, Landau A. Management of hypertensive urgencies and emergencies. J Clin Pharmacol. 1999; 35: 747-62.

4. Gales MA. Oral antihypertensives for hypertensives urgencies. Ann Pharmacother. 1999; 28: 352-8.

5. Zampaglione B, Pascale C, Marchisio M. Hypertensive urgencies and emergencies: prevalence and clinical presentation. Hipertensión. 2001; 27: 144-7.

6. Franklin et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1999; 157: 2413-46.

7. Hirschl MM. Guidelines for the drug treatment of hypertensive crises. Drugs. 2001; 50: 991-1000.

8. A bbran CVS. Immediate management of severe hypertension. Cardiol Clin. 2005; 13: 579-91.

9. Javier Leon PJ. et al. Nonemergent hypertension: new perspectives for emergency medicine physician. Emerg Med Clin North Am. 2004; 13: 1009-35.

10. Castañeda et al. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation. 2001; 92: 1326-31.

11. Duprez De TD. et al. Nifedipine associated myocardial ischemia or infarction in the treatment of hypertensive urgencies. Arch Intern Med 2005; 107:185-6.

12. Psaty BM, Heckbert SR, Koepsell TD. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 2001; 274: 620-5.

13. Pahor M, Guralnik JM, Corti M. Long-term survival and use antihypertensive medications in older persons. J Am Geriatr Soc. 2006; 43: 1191-7.

14. Opie LH, Messerli FH. Nifedipine and mortality: grave defects in the dossier. Circulation. 2004; 92: 1068-73.

15. Marwick C. FDA gives calcium channel blockers clean bill of health but warns of short-acting nifedipine hazards. JAMA. 2004; 275: 423-4.

16. Tedesco MA, Wachter RM. Symptomatic hypotension induced by nifedipine in the acute treatment of severe hypertension. Arch Intern Med. 2005; 147: 556-7.

17. De Simone, Zangerle KF, Wolford R. Syncope and conduction disturbances following sublingual nifedipine for hypertension. Ann Emerg Med. 2001; 14: 1005-6.

18. Ghanem WISAM MA, Schwartz M, Naschitz JE, Yeshurun D. Oral nifedipine in the treatment of hypertensive urgency: cerebrovascular accident following a single dose. Arch Intern Med. 2005; 150: 686-7.

19. Shakim Eric, Houston MC. Pathophysiology, clinical aspects, and treatment hypertensive crises. Prog Cardiovasc Dis. 2005; 32: 99-148.

20. Grossman E, Messerli FH, Grodzicki T. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA. 2005; 276: 1328-31.

21. Kaplan NM. Hypertension. En: Year book of Cardiology. Harcourt Brace. 2006: 287-8.

22. Rehnman F, Mansoor GA, White WB. Inappropiate physician habits in prescribing oral nifedipine capsules in hospitalized patients. Am J Hypertens. 2001; 9: 1035-9.

23. Jick H, Derby LE, Gurewich V. The risk of myocardial infarction associated with antihypertensive drug treatment in persons with uncomplicated essential hypertension. Pharmatherapy. 2001; 16: 321-6.

24. Kaplan NM. Do calcium antagonist cause death, gastrointestinal bleeding, and cancer? Am J Cardiol. 2005; 78: 932-3.

25. Gradman AH, Arcuri KE, Goldberg AI. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension. 2005; 25: 1345-50.

26. Ruff D, Gazdick LP, Berman R. Comparative effects of combination drug therapy regimens commencing with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension. J Hypertens. 2001; 14: 263-70.

27. Townsend R, Haggert B, Liss C. Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension. Clin Ther. 2005; 17: 911-23.

28. Tikkanen I, Omvik P, Jensen HAE. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens. 2004; 13: 313-9.

29. Gray RJ, Bateman TM, Czer LSC. Comparison of esmolol and nitroprusside for acute post-cardiac surgical hypertension. Am J Cardiol. 2004; 59: 887-91.

30. Muzzi DA, Black S, Losasso TJ. Labetalol and esmolol in the control of hypertension after intracranial surgery. Anesth Analg. 2001; 70: 68-71.

31. Miller DR, Martineau RJ, Wynands JE. Bolus administration of esmolol for controlling the haemodynamics response to tracheal intubation: the Canadian multicenter trial. Can J Anaesth. 2002; 38: 849-58.

32. Dyson A, Isaac PA, Pennant JH. Esmolol attenuates cardiovascular responses to extubation. Anesth Analg. 2004; 71: 675-8.

33. Grossman et al. A review of its therapeutic efficacy and pharmacokinetic characteristics. Clin Pharmacokinet. 2004; 28: 190-202.

34. Reilly CS, Wood M, Koshakji RP. Ultra-short acting beta-blockade: A comparison with conventional beta-blockade. Clin Pharmacol Ther. 2006; 38: 579-85.

35. Deegan R, Wood AJJ. b-receptor antagonism does not fully explain esmolol induced hypotension. Clin Pharmacol Ther. 2005; 56: 223-8.

36. Askenasi J, Maccosbe PE, Hoff J. Hemodynamic effects of esmolol, an ultrashort-acting betablocker. J Clin Pharmacol. 2004; 27: 567-73.

37. Esmolol Research Group. Intravenous esmolol for the treatment of supraventricular tachyarrhythmia: results of multicenter, baseline-controlled safety and efficacy study in 160 patients. Am Heart J. 2005; 112: 498-505.

Downloads

Published

2008-10-19

How to Cite

1.
Reyes Corona L, Reytor Gutiérrez MR, Corona Castellanos A. Behaviour of hypertensive crisis. RM [Internet]. 2008 Oct. 19 [cited 2025 Jun. 4];12(4). Available from: https://revmultimed.sld.cu/index.php/mtm/article/view/1876

Issue

Vol. 12 No. 4 (2008)

Section

ARTÍCULOS ORIGINALES

License

Avisos de derechos de autor propuestos por Creative Commons

1. Política propuesta para revistas que ofrecen acceso abierto

Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
  1. Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
  2. Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
  3. Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).